Establishment of Rat Liver Microsome-Hydrogel System for in Vitro Phase II Metabolism and Its Application to Study Pharmacological Effects of UGT Substrates

Zhe Zhang,Guo Ma,Caifu Xue,Hong Sun,Ziteng Wang,Xiaoqiang Xiang,Weimin Cai
DOI: https://doi.org/10.1016/j.dmpk.2019.01.005
IF: 2.041
2019-01-01
Drug Metabolism and Pharmacokinetics
Abstract:Studies on the efficacy evaluation of UDP-glucuronosyltransferases (UGTs) substrates often ignore the existence of active metabolites. However, the present study aims to establish an in-vitro Phase II metabolism system to predict their pharmacological effects after metabolism. Rat liver microsomes (RLMs) encapsulated in a F1270-Acr-Bis (FAB) hydrogel were placed in the incubation system. Baicalein (BA) was chosen as a model drug and the metabolic activity was investigated by quantitating the metabolite Baicalin (BG). The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was used to measure the cell viability in Traditional cell culture system (TCCS) and Microsome-hydrogel added to cell culture system for Phase II metabolism (MHCCS-II). Finally, MHCCS-II was applied to predict the metabolic effects of Oroxylin A (OA) and Wogonin (W). Compared to TCCS group, for HepG2 and MCF-7 cells, BA in MHCCS-II led to lower survival ratios of cells (P < 0.05), while for PC12 cells it led to higher survival ratios of cells (P < 0.01). For HepG2 cells, OA and W showed obviously enhanced tumor inhibition after metabolism with the IC50 of 32.7 +/- 2.9 mu M and 76.1 +/- 5.1 mu M, respectively (P < 0.01). In conclusion, the MHCCS-II could be a useful tool for studying the pharmacokinetics and pharmacodynamics of UGTs substrates. (C) 2019 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
What problem does this paper attempt to address?